These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 220567)

  • 1. [Survival and therapy of multiple myeloma. Apropos of 56 observed cases].
    Locatelli F; Giovanelli E; Neretto G; Furno F; Pellerito R
    Minerva Med; 1979 Mar; 70(13):925-33. PubMed ID: 220567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy of multiple myeloma. Review of the recent trials].
    Tribalto M; Arcese W; Colombo R; Pastore S; Franchii A
    Recenti Prog Med; 1981 Aug; 71(2):141-7. PubMed ID: 7031807
    [No Abstract]   [Full Text] [Related]  

  • 3. [Recent progress in chemotherapy of multiple myeloma].
    Tortarolo M; Cantore N; Russolillo S; Castaldo C; Buonanno G
    Recenti Prog Med; 1978 Jul; 65(1):44-68. PubMed ID: 370935
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
    Buonanno G; Tortarolo M; Valente A; Castaldo C; Russolillo S; Gonnella F
    Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
    Frei E; Schabel FM; Goldin A
    Cancer Res; 1974 Jan; 34(1):184-93. PubMed ID: 4520419
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy of multiple myeloma. Study of hospital patients: 81 cases in 16 years' observation].
    Monti G; Cereda UG; Pessina E; De Micheli N; Grisetti GC; Invernizzi F
    Minerva Med; 1983 Feb; 74(5):155-63. PubMed ID: 6828250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) (author's transl)].
    Bataille R; Morlock G; Rosenberg F; Sany J; Serre H
    Sem Hop; 1979 Sep 18-25; 55(31-32):1377-82. PubMed ID: 228415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polychemotherapy (COMP) treatment in myeloma patients. A preliminary report.
    Izzi T; Polchi P; Moretti L; Lucarelli G
    Haematologica; 1983; 68(3):381-91. PubMed ID: 6411532
    [No Abstract]   [Full Text] [Related]  

  • 11. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
    Iwata Y; Karitani Y; Tanaka I; Kobayashi T; Ohno T; Kageyama S; Katayama N; Kataoka Y; Kamio N; Ohota C
    Rinsho Ketsueki; 1984 Sep; 25(9):1380-7. PubMed ID: 6549187
    [No Abstract]   [Full Text] [Related]  

  • 13. [Combined cytostatic therapy of plasmacytoma].
    Albert P; Zsuzsa M
    Orv Hetil; 1977 Jul; 118(31):1855-6. PubMed ID: 887257
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
    Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M
    Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Extraskeletal diffusion of multiple myeloma. A clinico-pathological description of 4 cases].
    Cantore M; Smerieri F; Bucalossi A; Leoncini L
    Recenti Prog Med; 1991 Nov; 82(11):598-602. PubMed ID: 1763233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone.
    Gobbi M; Cavo M; Savelli G; Baccarani M; Tura S
    Haematologica; 1980 Aug; 65(4):437-45. PubMed ID: 6774915
    [No Abstract]   [Full Text] [Related]  

  • 18. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    Case DC; Lee DJ; Clarkson BD
    Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of Kahler's disease].
    Foa J; Carcassonne Y
    Sem Hop; 1976 Jan; 52(3):165-71. PubMed ID: 186874
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of plasmacytoma].
    Gassel WD; Sodomann CP
    Ther Ggw; 1980 Sep; 119(9):980-1005. PubMed ID: 7466705
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.